NCT00136019View on ClinicalTrials.gov

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Epilepsy
Interventions
DRUG

SPM 927

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY